NEWBURYPORT, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, announced that industry veteran Scott VanderWel has joined the company as Business Development Manager, and is based in San Diego, the company’s first office outside Massachusetts.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/23be7a05-72f9-4203-a4eb-9aabe92258e1
VanderWel will lead sales and marketing efforts for the West Coast. He will leverage his local connections and help to raise PCI Synthesis’ profile among the West Coast’s vibrant community of emerging biotech and biopharma companies.
“The addition of Scott to our team helps us to better support West Coast-based biotech, an important area of growth for us,” said Ed Price, President of PCI Synthesis. “Scott has been successful in business development over the last decade because he spent the prior decade working in the lab. Having been on the sponsor side, with a clear understanding of what works, Scott is able to use that experience to help us better serve our West Coast partners.”
Prior to joining PCI Synthesis, VanderWel served as Director of Business Development at Albany Molecular Research and BPS Bioscience. He got his start working in a number of capacities for Parke-Davis (now Pfizer), where he worked for nearly 12 years in the chemistry labs and managed projects with CROs in North America, Europe and India.
“I spent the first half of my career doing science and the second half on the business side, finding solutions to challenges for emerging biotech and biopharma companies. My job is to make the right connections for sponsors and for PCI Synthesis,” VanderWel said. “That combination positions me to help our customers because I used to do what they do. I understand their goals, and I’m committed to working on making sure we deliver what our sponsors need. Our growth depends on their success, and we’ve got two decades of successful innovation to solve hard science problems.”
VanderWel earned an MBA from Michigan State University’s Eli Broad Graduate School of Management; an MS in Chemistry from Eastern Michigan University and a BS in Chemistry from the University of Michigan. He holds three patents and has been published in a number of publications, including the Journal of Medicinal Chemistry.
About PCI Synthesis
PCI Synthesis is a Pharmaceutical Development CMO (Contract Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.
Source: PCI Synthesis